Breast cancer metastasis suppressor 1 (BRMS1)

Breast cancer metastasis suppressor 1 (BRMS1) is a nuclear protein primarily functioning as a transcriptional co-repressor in chromatin remodeling complexes (Sin3A–HDAC) that suppresses metastasis by epigenetically repressing genes involved in cell migration, invasion, and survival, including those regulating anoikis[4][3]. Although not a classic receptor or enzyme, BRMS1 is considered a promising therapeutic and prognostic target because its loss or decreased expression is associated with increased metastatic potential and poor outcomes, particularly in breast cancer[4][3]. Its mechanism involves histone deacetylation at promoters of metastasis-associated genes, interactions with ARID4A, SUDS3, and modulation of multiple cellular pathways such as NF-κB, EGFR, FAK, and AKT[4][3]. The clinical significance is highlighted by evidence that restoration of BRMS1 suppresses metastasis without impacting primary tumor growth[4][2][3]. Direct drug targeting is not established; current therapeutic interest is in drugs (e.g., HDAC inhibitors) that might influence BRMS1 activity through epigenetic or complex-associated mechanisms[4].

Other names

BRMS1DKFZP564A063Breast cancer metastasis-suppressor 1Breast cancer metastasis suppressor 1

Drugs targeting HDAC/Sin3A complex may modulate BRMS1-mediated epigenetic silencing of oncogenes